Novartis's Bexsero Receives FDA Breakthrough Therapy Designation - - BioPharm International


Novartis's Bexsero Receives FDA Breakthrough Therapy Designation

Novartis reported that Bexsero has received a breakthrough therapy designation from FDA. Bexsero is already approved in Europe, Canada, and Australia to help protect against meningococcal disease caused by serogroup B (meningitis B).

This announcement comes after a decision from regulators in the UK, where the Joint Committee on Vaccination and Immunization recommended the inclusion of Bexsero in the country's National Immunization Program forroutine use in infants two years and up.

Source: Novartis
blog comments powered by Disqus



NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines

Click here